Cooley advised Vectiv Bio Holding on its $146.6 million initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. VectivBio, whose securities now trade on the Nasdaq Global Market under the symbol “VECT,” is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Partners Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.
